|Day Low - High||0.32 - 0.36|
|Year Low - High||0.28 - 1.85|
More Healthcare/Biotech NewsDecember 3, 2017
Aetna CEO Mark Bertolini Interview on Healthcare’s Future Focus & CVS BuyoutDecember 1, 2017
Pfizer Granted Rights to Develop Novel Antifungal Medicine in AsiaNovember 29, 2017
Vista Partners Recently Published An Update Report on Health Insurance Innovations, Inc. (NASDAQ: HIIQ)November 3, 2017
Health Insurance Innovations (HIIQ) Jumps +11.11% Today Post Q3 Beat -See Earnings Call TranscriptNovember 1, 2017
Health Insurance Innovations (HIIQ) Reports Record Q3 & Increases 2017 Full Year GuidanceOctober 31, 2017
Drug Developing Giant Pfizer (PFE) Beats with Q3 Results & CommentaryOctober 25, 2017
UnitedHealth Group (NYSE: UNH) Exceeds Q3 ExpectationsOctober 25, 2017
Johnson & Johnson (NYSE: JNJ) announced a total of $19.7B in sales
Approximately one in eight women will be diagnosed with breast cancer during their lifetime. Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year. Tamoxifen has been widely used for over 30 years for breast cancer. Additional research has shown that it is the metabolites of tamoxifen, of which endoxifen is the most active, that have potential therapeutic value.
Atossa is the only company in the WORLD attempting to conquer breast cancer the way they are and have stated “The best way to treat a disease is to prevent it in the first place.” They are developing a topical drug, a lotion applied to each breast, to treat a condition known as high breast density. Third-party studies have shown that high breast density increases the risk of developing breast cancer in some women. Breast density is diagnosed by mammography and approximately 10 million women have high density in the U.S. Tamoxifen has been demonstrated to reduce density and the incidence of breast cancer. However, tamoxifen can have serious side effects because, as a drug taken orally, it is delivered “systemically” meaning it travels throughout the body to other areas the drug is not needed. The goal with their topical endoxifen program is to treat high breast density with a local, topical drug.
Atossa is also developing a new way to deliver pharmaceuticals – through microcatheters (small tubes that can be inserted with anesthetic, through the nipple) so that pharmaceuticals can be targeted to the tissue where breast cancer actually grows.
Their proprietary oral and topical forms of endoxifen are the subject of a comprehensive Phase 1 clinical study in healthy women in Australia. Their patented microcatheter technology is in a Phase 2 clinical study that is also currently enrolling patients.
“Too Close For Comfort” Vista Partners Weekly Market Update
Vista Partners has published its Weekly Market Update for the week of December 2, 2017, titled “Too Close For Comfort” Vista Partners Weekly Market Update 12-9-2017 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the
How Do You Like The Sound of “24K”?
Vista Partners has published its Weekly Market Update for the week of December 2, 2017, titled “24K” Vista Partners Weekly Market Update 12-2-2017 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the
“Will the Bull Market Continue to Run?” Vista Partners Publishes November Macroeconomic & Investment Newsletter
Vista Partners (“Vista”) has published November’s FREE Macroeconomic & Investment Monthly Newsletter, “Will the Bull Market Continue to Run?” Vista’s monthly newsletter contains investment considerations for Biotech, Cloud Services, Energy, Fintech, Healthcare, Manufacturing, Materials, SaaS, and Technology. Vista Partners centers its Coverage on the Dow